Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
NRNurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc. (NRIX)

NASDAQ · Currency in USD
$25.34 ▼ -0.17 (-0.67%)
At close: Oct 23, 4:00 PM ET. Market closed.
$25.34 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$25.51
Open
$25.15
Day's Range
$24.78 – $25.49
52 Week Range
$11.19 – $28.23
Volume
1,910,298
Avg. Volume
1,728,794
Market Cap
$2.77B
Beta (5Y Monthly)
1.82
PE Ratio (TTM)
10.10
EPS (TTM)
$2.64
Earnings Date
Jan 27, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$35.58

Profile: Nurix Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
317
CEO
Arthur T. Sands

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.

Earnings

Next report: Wed, Jan 27, 2027
EPS estimate -$0.46 · Revenue est. $37.95M
DateEst.Actual
Oct 12, 2026-$0.60$4.73Beat
Jul 9, 2026-$0.72-$0.81Miss
Apr 8, 2026-$0.76-$0.79Miss
Jan 28, 2026-$0.84-$0.82Beat
Oct 9, 2025-$0.84-$1.03Miss
Jul 9, 2025-$0.71-$0.52Beat

Analyst view

Consensus price target
$35.58 ▲ +40.4%
Range $31.00 – $45.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on NRIX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.